Mesothelioma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mesothelioma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials https://clinicaltrials.eu/trial/56496/ Wed, 29 Apr 2026 14:29:10 +0000 https://clinicaltrials.eu/trial/56496/ This study focuses on evaluating a medication called tazemetostat, which is given as a film-coated tablet taken by mouth. The study aims to assess the long-term safety of this medication in patients who have previously been treated with tazemetostat in other clinical trials and have shown benefit from the treatment.

The study will monitor patients who continue taking tazemetostat either alone or in combination with other approved or experimental medications. During the study, researchers will track any side effects that may occur and how well patients tolerate the medication over an extended period. The medication will be provided according to each patient’s previous treatment plan.

Participants will be monitored for various health measures, including their blood cell counts, kidney function, and liver function. The study will also track how long patients survive while receiving the treatment. This is an open-label study, which means all participants will receive the active medication, and there is no use of a placebo.

]]> Study on Calcium Folinate to Reduce Pemetrexed Side Effects in Patients with Non-Small Cell Lung Cancer, Mesothelioma, or Thymoma https://clinicaltrials.eu/trial/study-on-calcium-folinate-to-reduce-pemetrexed-side-effects-in-patients-with-non-small-cell-lung-cancer-mesothelioma-or-thymoma/ Wed, 29 Apr 2026 14:24:57 +0000 https://clinicaltrials.eu/trial/study-on-calcium-folinate-to-reduce-pemetrexed-side-effects-in-patients-with-non-small-cell-lung-cancer-mesothelioma-or-thymoma/ This clinical trial is focused on studying the effects of a treatment for certain types of cancer, specifically Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Thymoma. The treatment being tested is called Rescuvolin, which contains the active substance calcium folinate. This medication is being used to see if it can help reduce side effects caused by another cancer treatment called pemetrexed.

The purpose of the study is to evaluate how well calcium folinate can prevent or lessen the side effects, particularly those affecting blood cells, when used alongside pemetrexed. Participants in the study will be randomly assigned to receive either the calcium folinate treatment or a placebo, in addition to their regular cancer treatment. The study will monitor the participants over a period of time to observe any changes in their health, especially focusing on blood cell counts and other potential side effects.

Throughout the study, participants will take the medication in the form of tablets, and their health will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether calcium folinate can effectively reduce the side effects of pemetrexed, potentially improving the quality of life for patients undergoing treatment for these types of cancer.

]]>